BR112016028567A2 - método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea - Google Patents

método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea

Info

Publication number
BR112016028567A2
BR112016028567A2 BR112016028567A BR112016028567A BR112016028567A2 BR 112016028567 A2 BR112016028567 A2 BR 112016028567A2 BR 112016028567 A BR112016028567 A BR 112016028567A BR 112016028567 A BR112016028567 A BR 112016028567A BR 112016028567 A2 BR112016028567 A2 BR 112016028567A2
Authority
BR
Brazil
Prior art keywords
fgf23
treating
condition
related disease
bone remodeling
Prior art date
Application number
BR112016028567A
Other languages
English (en)
Portuguese (pt)
Inventor
Kakkis Emil
San Martin Javier
Sudo Tomohiro
Original Assignee
Kyowa Hakko Kirin Co Ltd
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, Ultragenyx Pharmaceutical Inc filed Critical Kyowa Hakko Kirin Co Ltd
Priority to BR122023023102-3A priority Critical patent/BR122023023102A2/pt
Publication of BR112016028567A2 publication Critical patent/BR112016028567A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112016028567A 2014-06-09 2015-05-29 método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea BR112016028567A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023023102-3A BR122023023102A2 (pt) 2014-06-09 2015-05-29 Uso de um anticorpo anti-fgf23 para o tratamento de um distúrbio hipofosfamético associado a níveis e/ou atividade anormais do fator de crescimento de fibroblastos 23 (fgf23)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09
PCT/US2015/033226 WO2015191312A1 (en) 2014-06-09 2015-05-29 The effective and efficient control of serum phosphate for optimal bone formation

Publications (1)

Publication Number Publication Date
BR112016028567A2 true BR112016028567A2 (pt) 2018-01-30

Family

ID=54769049

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016028567A BR112016028567A2 (pt) 2014-06-09 2015-05-29 método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea
BR122023023102-3A BR122023023102A2 (pt) 2014-06-09 2015-05-29 Uso de um anticorpo anti-fgf23 para o tratamento de um distúrbio hipofosfamético associado a níveis e/ou atividade anormais do fator de crescimento de fibroblastos 23 (fgf23)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122023023102-3A BR122023023102A2 (pt) 2014-06-09 2015-05-29 Uso de um anticorpo anti-fgf23 para o tratamento de um distúrbio hipofosfamético associado a níveis e/ou atividade anormais do fator de crescimento de fibroblastos 23 (fgf23)

Country Status (25)

Country Link
US (5) US10639360B2 (https=)
EP (3) EP3845245B1 (https=)
JP (2) JP6808493B2 (https=)
KR (4) KR102947335B1 (https=)
CN (1) CN106604743A (https=)
AR (2) AR100689A1 (https=)
AU (1) AU2015275128C1 (https=)
BR (2) BR112016028567A2 (https=)
CA (1) CA2949234C (https=)
CL (1) CL2016003179A1 (https=)
CY (1) CY1124328T1 (https=)
DK (2) DK3151859T3 (https=)
ES (2) ES3040805T3 (https=)
FI (1) FI3845245T3 (https=)
HR (2) HRP20210250T1 (https=)
HU (2) HUE053271T2 (https=)
LT (2) LT3845245T (https=)
MX (2) MX381052B (https=)
PE (1) PE20170248A1 (https=)
PL (2) PL3845245T3 (https=)
PT (2) PT3845245T (https=)
RS (2) RS61443B1 (https=)
SI (2) SI3151859T1 (https=)
SM (2) SMT202500342T1 (https=)
WO (1) WO2015191312A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
BR112021019337A2 (pt) * 2019-03-29 2021-12-07 Atarga Llc Anticorpo anti-fgf23
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
EP4676955A2 (en) * 2023-03-10 2026-01-14 Ultragenyx Pharmaceutical Inc. Human fgf23-binding antibodies with improved affinity and efficacy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP2233571B1 (en) 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP4527982B2 (ja) * 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
EP1833848A2 (en) * 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.

Also Published As

Publication number Publication date
CA2949234A1 (en) 2015-12-17
MX2021003740A (es) 2021-05-27
ES3040805T3 (en) 2025-11-05
JP2017524656A (ja) 2017-08-31
RS61443B1 (sr) 2021-03-31
SI3845245T1 (sl) 2025-10-30
PL3845245T3 (pl) 2025-12-22
LT3845245T (lt) 2025-09-25
EP3151859B1 (en) 2020-11-25
WO2015191312A1 (en) 2015-12-17
KR102947335B1 (ko) 2026-04-03
PT3845245T (pt) 2025-09-16
AR100689A1 (es) 2016-10-26
US10639360B2 (en) 2020-05-05
KR20170013993A (ko) 2017-02-07
US20260035449A1 (en) 2026-02-05
EP3845245A1 (en) 2021-07-07
HRP20251099T1 (hr) 2025-11-07
JP2021050226A (ja) 2021-04-01
SI3151859T1 (sl) 2021-06-30
PT3151859T (pt) 2021-02-03
US20200330575A1 (en) 2020-10-22
SMT202500342T1 (it) 2025-11-10
ES2851674T3 (es) 2021-09-08
KR20210099180A (ko) 2021-08-11
US11771748B2 (en) 2023-10-03
CN106604743A (zh) 2017-04-26
KR20260051107A (ko) 2026-04-15
HUE073105T2 (hu) 2025-12-28
LT3151859T (lt) 2021-03-25
JP6993490B2 (ja) 2022-02-03
SMT202100096T1 (it) 2021-03-15
EP4647444A3 (en) 2026-01-21
US12358976B2 (en) 2025-07-15
US20220133871A1 (en) 2022-05-05
MX2016016296A (es) 2017-10-12
EP3151859A4 (en) 2018-01-17
KR20240093956A (ko) 2024-06-24
EP3845245B1 (en) 2025-06-25
HRP20210250T1 (hr) 2021-04-02
CA2949234C (en) 2022-03-22
US20240115683A1 (en) 2024-04-11
DK3151859T3 (da) 2021-02-15
US20150353633A1 (en) 2015-12-10
EP3151859A1 (en) 2017-04-12
EP4647444A2 (en) 2025-11-12
CL2016003179A1 (es) 2017-11-03
HUE053271T2 (hu) 2021-06-28
PE20170248A1 (es) 2017-04-14
AU2015275128A1 (en) 2016-12-08
BR122023023102A2 (pt) 2024-03-05
JP6808493B2 (ja) 2021-01-06
FI3845245T3 (fi) 2025-09-09
AR131056A2 (es) 2025-02-12
RS67294B1 (sr) 2025-11-28
PL3151859T3 (pl) 2021-07-26
DK3845245T3 (da) 2025-09-15
AU2015275128C1 (en) 2020-02-13
AU2015275128B2 (en) 2019-10-31
US11202822B2 (en) 2021-12-21
MX381052B (es) 2025-03-12
CY1124328T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
BR112016028567A2 (pt) método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
PE20191251A1 (es) Moleculas de fijacion para el tratamiento del cancer
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
PE20150887A1 (es) Compuestos de benceno sustituidos
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
MX373187B (es) Terapia de combinación para tratar cáncer.
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112017018092A2 (pt) composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
BR112016021648A2 (pt) novos compostos
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112018010012A2 (pt) regimes de dosagem de melflufen para câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ULTRAGENYX PHARMACEUTICAL INC. (US) ; KYOWA KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: ULTRAGENYX PHARMACEUTICAL INC. (US) ; KYOWA KIRIN CO., LTD. (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023023102-3 PROTOCOLO 870230097473 EM 03/11/2023 20:45.